| Molecule | Cat. No. | Product Name | Species | Host | Structure | Purity | Activity | Size&Price |
|---|---|---|---|---|---|---|---|---|
| LGR5 | Cynomolgus LGR5 / GPR49 protein, His Tag | Cynomolgus | HEK293 | ![]() | SDS-PAGE | $360.00 100ug | ||
| LGR5 | Human LGR5 / GPR49 protein, Fc Tag | Human | HEK293 | ![]() | SDS-PAGE | $380.00 100ug | ||
| LGR5 | Human LGR5 / GPR49 Protein, His Tag, low endotoxin | Human | HEK293 | ![]() | SDS-PAGE | $435.00 100ug | ||
| LGR5 | Avitag LG5-H82E4 | Biotinylated Human LGR5 / GPR49 (22-561) Protein, His,Avitag™ | Human | HEK293 | ![]() | SDS-PAGE | $360.00 25ug | |
| LGR5 | Mouse LGR5 / GPR49 Protein, Fc Tag | Mouse | HEK293 | ![]() | SDS-PAGE | $360.00 100ug |
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Petosemtamab | MCLA-158 | Phase 2 Clinical | Merus Nv | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms | Details |
| CNA-3103 | CNA-3103 | Phase 2 Clinical | Carina Biotech Pty Ltd | Colorectal Neoplasms | Details |